Product Name :
OBI-3424
Description:
OBI-3424 (TH-3424) is a prodrug that is selectively converted by AKR1C3 (aldo-keto reductase 1C3) to a potent DNA-alkylating agent. OBI-3424 can be used for hepatocellular carcinoma, castrate-resistant prostate cancer, and acute lymphoblastic leukemia (ALL) research.
CAS:
2097713-68-1
Molecular Weight:
460.42
Formula:
C21H25N4O6P
Chemical Name:
(1R)-1-{3-[3-(dimethylcarbamoyl)phenoxy]-4-nitrophenyl}ethyl bis(aziridin-1-yl)phosphinate
Smiles :
CN(C)C(=O)C1=CC(=CC=C1)OC1=CC(=CC=C1[N+]([O-])=O)[C@@H](C)OP(=O)(N1CC1)N1CC1
InChiKey:
NWGZZGNICQFUHV-OAHLLOKOSA-N
InChi :
InChI=1S/C21H25N4O6P/c1-15(31-32(29,23-9-10-23)24-11-12-24)16-7-8-19(25(27)28)20(14-16)30-18-6-4-5-17(13-18)21(26)22(2)3/h4-8,13-15H,9-12H2,1-3H3/t15-/m1/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
OBI-3424 (TH-3424) is a prodrug that is selectively converted by AKR1C3 (aldo-keto reductase 1C3) to a potent DNA-alkylating agent. OBI-3424 can be used for hepatocellular carcinoma, castrate-resistant prostate cancer, and acute lymphoblastic leukemia (ALL) research.|Product information|CAS Number: 2097713-68-1|Molecular Weight: 460.42|Formula: C21H25N4O6P|Chemical Name: (1R)-1-{3-[3-(dimethylcarbamoyl)phenoxy]-4-nitrophenyl}ethyl bis(aziridin-1-yl)phosphinate|Smiles: CN(C)C(=O)C1=CC(=CC=C1)OC1=CC(=CC=C1[N+]([O-])=O)[C@@H](C)OP(=O)(N1CC1)N1CC1|InChiKey: NWGZZGNICQFUHV-OAHLLOKOSA-N|InChi: InChI=1S/C21H25N4O6P/c1-15(31-32(29,23-9-10-23)24-11-12-24)16-7-8-19(25(27)28)20(14-16)30-18-6-4-5-17(13-18)21(26)22(2)3/h4-8,13-15H,9-12H2,1-3H3/t15-/m1/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 50 mg/mL (108.{{Encequidar} site|{Encequidar} Membrane Transporter/Ion Channel|{Encequidar} Protocol|{Encequidar} In Vivo|{Encequidar} supplier|{Encequidar} Autophagy} 60 mM; Need ultrasonic).{{Tusamitamab} web|{Tusamitamab} Purity & Documentation|{Tusamitamab} Data Sheet|{Tusamitamab} supplier|{Tusamitamab} Epigenetic Reader Domain} |Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.PMID:23996047 |Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|OBI-3424 exerts potent cytotoxicity against the H460 lung cancer cell line (IC50 of 4.0 nM). OBI-3424 exhibits potent cytotoxicity, in particular against cell lines derived from T-ALL with high AKR1C3 expression, with IC50 values in the low nM range. OBI-3424 also exerts potent cell killing against ALL PDXs, and the median IC50 values were 60.3 nM for B-ALL, 9.7 nM for T-ALL and 31.5 nM for ETP-ALL.|In Vivo:|OBI-3424 (0.5-2.5 mg/kg; i.p.; once weekly; for 3 weeks) treatment induces regressions in PDXs mice and results in prolongation of mouse event-free survival.|Products are for research use only. Not for human use.|
